Holen Sie sich die Stockscreener-App
1.40
11.11%
0.14
Vorhandelsmarkt:
1.32
-0.08
-5.71%
Renovorx Inc Aktie (RNXT) Neueste Nachrichten
What is HC Wainwright's Forecast for RenovoRx Q3 Earnings? - MarketBeat
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers - MarketBeat
RenovoRx (NASDAQ:RNXT) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Renovorx Stock Price Forecast. Should You Buy RNXT? - StockInvest.us
H.C. Wainwright Maintains RenovoRx(RNXT.US) With Buy Rating, Maintains Target Price $3 - Moomoo
RenovoRx Inc (NASDAQ: RNXT) Stock Price, News & Analysis - kalkine.ca
RenovoRx earnings beat by $0.02, revenue topped estimates - Investing.com Nigeria
RenovoRx Inc (RNXT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ... - Yahoo Finance
RenovoRx, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
RenovoRx Q2 Earnings Call Highlights - MarketBeat
RenovoRx (RNXT) Q2 2026 Earnings Call Transcript - AOL.com
RenovoRx Q2 revenue surges 115% YoY to $909,000; raises FY26 guidance - scanx.trade
RenovoRx raises FY26 sales guidance to $3.75M-$4.25M vs $3.2M est - scanx.trade
Earnings call transcript: RenovoRx posts Q2 2026 beat, lifts guidance By Investing.com - Investing.com Canada
RenovoRx Inc reports results for the quarter ended June 30Earnings Summary - TradingView
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth - Investing News Network
RenovoRx (NASDAQ:RNXT) Posts Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Earnings call transcript: RenovoRx posts Q2 2026 beat, lifts guidance - Investing.com
RenovoRx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Renovorx, Inc. Increases Earnings Guidance for Full Year 2026 - marketscreener.com
RenovoRx Inc (RNXT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer - Investing News Network
RenovoRx completes enrollment in phase III pancreatic cancer trial - Investing.com
RenovoRx Inc (RNXT) Q2 2026: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Renovorx Achieves Major Milestone With Full Enrollment In Phase Iii Tiger-Pac Trial For Locally Advanced Pancreatic Cancer - TradingView
RenovoRx Inc (RNXT) Q2 2026: Everything You Need To Know Ahead O - GuruFocus
RenovoRx pancreatic cancer trial closes enrollment; 78 deaths occurred - Stock Titan
EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027 - Benzinga
RenovoRx Inc expected to post a loss of 7 cents a shareEarnings Preview - TradingView
RenovoRx (RNXT) Climbs 3.12% to $1.16 as Oncology Pipeline Keeps Micro-Cap in FocusNarrow Range Breakout - dars.gov.et
RenovoRx reports RenovoCath’s first clinical use in sarcoma - Medical Device Network
RenovoRx Inc (RNXT) Stock News Today - TradingKey
RenovoRx Announces First Commercial Clinical Use of RenovoCath in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors - marketscreener.com
Earnings Preview: RenovoRx to Report Financial Results Post-market on August 12 - Moomoo
RenovoRx’s RenovoCath used in sarcoma treatment for first time By Investing.com - Investing.com Nigeria
RenovoRx’s RenovoCath used in sarcoma treatment for first time - Investing.com
RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors - The Manila Times
A Sarcoma Patient Is Receiving Local Chemotherapy via RenovoCath - Stock Titan
RenovoRx Announces First Commercial Clinical Use Of RenovoCath In Sarcoma Patient Treatment - marketscreener.com
RenovoRx (RNXT) Gains 2.4% to $1.06: Micro-Cap Biotech Presses Against ResistanceMA Crossover - dars.gov.et
RenovoRx Highlights TAMP Platform in Upcoming Oncology Webinar - TipRanks
RenovoRx to Present TAMP Platform, TIGeR-PaC Trial Update at JonesTrading Webinar Aug 13 - TradingView
RenovoRx, Inc. (NASDAQ:RNXT): Are Analysts Optimistic? - webull.com
RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th - marketscreener.com
RenovoRx Webinar to Explore Local Chemotherapy for Pancreatic Cancer - Stock Titan
RenovoRx to highlight TAMP platform and record Q1 2026 sales at webinar - scanx.trade
RNXT|RenovoRx Inc|Price:1.040|Chg%:+0.082 - TradingKey
RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET - The Manila Times
Healthy You: United Regional’s cancer center marks its first year - AOL.com
RenovoRx Inc (RNXT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
RenovoRx Inc (RNXT) Income Statement - TradingKey
RNXT|RenovoRx Inc|Price:1.120|Chg%:-0.030 - TradingKey
RenovoRx Inc (RNXT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RenovoRx Inc (RNXT) Balance Sheet - TradingKey
RenovoRx Inc (RNXT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
RenovoRx Inc (RNXT) Valuation: PE, PB & Fair Value Analysis - TradingKey
RenovoRx Market Sentiment - Benzinga España
RenovoRx (RNXT) Edges Higher Amid Key Support; Technical Indicators Point to ConsolidationTRIN Signal - dars.gov.et
RenovoRx, Inc. Revenue Breakdown – NASDAQ:RNXT - TradingView
RenovoRx Inc (RNXT) Cash Flow - TradingKey
RNXT|RenovoRx Inc|Price:0.865|Chg%:+0.011 - TradingKey
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):